A New Framework to Engineer Breakthrough Value for Medicines
In an era where the biopharmaceutical landscape is rapidly evolving, a comprehensive approach to demonstrating and communicating the real-world value of medical advances has never been more important – but commercialising biopharmaceutical advancements has never been more challenging or fraught with risk.
In a new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’ – explore why success is now predicated on an evidence-based, stakeholder-specific demonstration of value, with real-world outcomes, measurable economic impact, and assets designed to fit today’s healthcare system.
Biopharma is at a paradoxical moment and scientific innovation is sprinting ahead, but the path to market has never been slower, riskier, or more expensive. Breakthroughs alone aren’t enough to win. Companies must demonstrate value early, make sharper bets, and navigate an environment where science, economics, and policy are colliding in ways the industry has never faced before.
The white paper ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’ explains why the old drug development and commercialisation playbooks no longer provide the right guidance and pathway to success in the marketplace. Stronger, earlier, and stakeholder-specific evidence of value secures funding, unlocks access, earns trust, and determines if an innovation reaches patients. Today’s challenges demand not just new medicines, but an evolution of the evidence that proves their value.
To this end, Lumanity’s white paper suggests a new framework to fit, taking into account evidence, engagement, tech & AI, and strategy. It looks at foundational elements, such as a carefully crafted asset profile that is built on a deep understanding of health system stakeholder needs, as well as an evidence strategy, generation, and engagement plan that clearly demonstrates and communicates the real-world value and economic impact of treatments to each key health system stakeholder – including payers, providers, regulators, and patients.
Download the white paper ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’ here. The commercialisation process has been transformed; learn how to adapt – and succeed – today.
About Lumanity
Lumanity is a leading global strategic partner for biopharmaceutical companies. We engineer breakthrough value to tackle our clients’ toughest challenges and transform lives. By combining deep scientific, clinical, medical, regulatory, and commercial expertise with advanced technology and AI-driven tools, Lumanity guides complex decision-making and execution across the entire medicine value creation journey.
With 1,200 highly specialized experts working in more than 50 countries, and offices in North America, the UK, the EU, and Asia, we collaborate with nearly all of the top pharmaceutical companies and over 100 biotechs worldwide.
Our integrated approach brings together strategy, evidence, engagement, and technology—helping clients navigate market complexities with confidence, accelerate commercial success, and ultimately improve patient health outcomes.
